Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Autonomix Medical (NASDAQ: AMIX) is a medical device company dedicated to transforming the diagnosis and treatment of diseases or disorders related to the nervous system. At the core of Autonomix's innovative approach is a first-in-class technology platform featuring a catheter-based microchip sensing array. This technology boasts an unprecedented ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies. This breakthrough has paved the way for transvascular diagnosis and treatment of nervous system diseases virtually anywhere in the body, offering a new horizon of medical possibilities and market opportunities. Clinical Studies In Pancreatic Cancer Pain Autonomix has initiated its first clinical study targeting pancreatic cancer pain, marking a significant milestone in its ongoing medical innovation. Pancreatic cancer represents a considerable unmet medical need, particularly concerning pain management. Effective solutions in this area are critically needed, as current relief options for pancreatic diseases are limited to drugs like opioids. In light of that, the initiation of these clinical studies represents a crucial step toward addressing this substantial healthcare challenge for suffering patients. Market Opportunities In addition to addressing the pain relief needs of patients, Autonomix’s technology presents significant market opportunities across various medical fields. By accurately targeting the nervous system, Autonomix aims to address unmet needs and improve treatments for a wide range of conditions including but not limited to: Pancreatic Cancer Pain: The successful application of Autonomix's technology in pancreatic cancer pain management would not only help pancreatic cancer patients find relief from pain but also unlocks significant market potential. Pancreatic cancer pain management is part of a $2.2 billion market for pancreatic cancer treatment. Chronic Pain: This market presents a significant opportunity estimated at $75 billion. Conditions such as lower back pain, pelvic pain, urinary tract pain, digestive disorders and other tumor-related pain are prevalent and often inadequately managed with current therapies, particularly opioids. Autonomix's technology offers the potential to significantly reduce or eliminate the dependence on opioids, providing a safer and more effective solution for chronic pain management. Cardiovascular Diseases: With a market opportunity estimated at $23 billion, Autonomix's technology could revolutionize the treatment of conditions like hypertension and cardiovascular disease. By targeting the nervous system's role in these diseases, more precise and effective treatments could be developed. Pulmonary Diseases: Chronic obstructive pulmonary disease (COPD) is another area where Autonomix's technology could have a substantial impact. The market for COPD treatments is estimated to be around $18 billion with considerable growth ahead, driven by the need for more effective and less side-effect-prone therapies. Autonomix's approach could provide a new paradigm in managing this debilitating condition. Meeting Unmet Needs with Innovative Solutions Current drug therapies for many of these conditions often come with significant side effects and do not adequately address the underlying issues. Autonomix's technology offers a promising alternative by providing targeted, nerve-based treatments that could improve patient outcomes and quality of life. This innovative approach aligns with Autonomix's mission to dramatically enhance the lives of millions by enabling precise and effective nerve-targeted treatments. In doing so, Autonomix can both detect and ablate malfunctioning nerves in one simple procedure, effectively opening new treatment options in the field of electrophysiology. The Full Opportunity Autonomix Medical sits at the forefront of a potential revolution in medical treatment for diseases driven by the nervous system. The company’s advanced technology platform not only offers hope for better management of pancreatic cancer pain, but also opens the door to addressing numerous other conditions with significant unmet need. By providing physicians with powerful new tools for diagnosis and treatment, Autonomix is poised to make a profound impact on the future of healthcare. Featured photo by Irwan on Unsplash. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

June 06, 2024 09:00 AM Eastern Daylight Time

Image

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

MarketJar

Disseminated on behalf of CERo Therapeutics Holdings, Inc. Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new lease on life. The first CAR T-cell therapy was only approved in 2017, but it’s already having a significant impact in the cancer treatment market. The latest success story comes from Sandra Hajlo, who just became the first person in Manitoba to be declared cancer-free following CAR T-cell therapy. 1 Initially diagnosed with stage four B-cell lymphoma in 2015, Hajlo underwent successful chemotherapy. However, eight years later, her cancer returned, leading to another battle with the disease. After a misdiagnosis of scoliosis, a CT scan revealed her cancer had come back. Her oncologist recommended CAR T-cell therapy, a new treatment where T-cells are modified to target cancer cells, making her the first recipient of this therapy at CancerCare Manitoba. Dr. David Szwajcer, Manitoba Blood & Marrow Transplant Director at CancerCare Manitoba, explained that the CAR T-cells are collected, sent to a U.S. facility for modification, and then reintroduced to the patient. Hajlo described the procedure as quick and straightforward, taking only 20 minutes. After undergoing CAR T-cell therapy in December 2023, Hajlo learned in April 2024 that the treatment was successful, and she is cancer-free once again, expressing her gratitude for the second chance at life. CAR T-cell therapy does not guarantee survival, with about half of the patients not responding,but it has shown promising results in many cases. CERo Therapeutics Holdings (NASDAQ:CERO) is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics. CERo Therapeutics is unrelated to CancerCare Manitoba and had no role in the CAR T-cell therapy described above. Nevertheless, CERo Therapeutics believes that the success of the CAR T-cell therapy in Manitoba may provide an indication of the potential for its proprietary CER-T (chimeric engulfment receptor) cell therapy. CAR-T cell treatment has a steep price tag and some potential serious side effects including secondary cancer developing 2 as well as cytokine release syndrome (CRS), 3 which causes your immune system to go into overdrive and is potentially life threatening. CER-T cell therapy may provide a more cost-effective alternative with fewer side effects. CERo Advances Innovative Cancer Immunotherapy CERo Therapeutics (NASDAQ:CERO) developed CER-T cells to enhance efficiency and reduce side effects compared to traditional therapies by leveraging the body's natural tumor-fighting mechanisms. CER-T cells achieve this through direct tumor killing and by amplifying the body's anti-tumor immune response, and additionally by presenting cancer cell fragments to other immune cells, drawing these cells to attack the tumor. Peer-reviewed data shows that CER-T cells have at least eight anticancer functions, offering potent, durable, and low-toxicity therapeutic benefits, with the capability to completely eliminate tumors. The company has validated these findings in 10 animal experiments, including a study on Acute Myeloid Leukemia (AML) published in March 2024. CERo Therapeutics believes CER-T cells offer greater therapeutic potential than currently approved chimeric antigen receptor (CAR-T) cell therapy, potentially targeting both hematological malignancies and solid tumors. The company plans to begin clinical trials for its lead product candidate, CER-1236, in 2024 for treating hematological malignancies. CERo has been diligently completing pre-clinical studies and documentation necessary to initiate clinical trials after gaining approval from the FDA for its Investigational New Drug (IND) Application. CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) has successfully completed toxicity studies for CER-1236, a critical step before applying to the FDA for approval to begin human trials. With these studies showing that CER-1236 can be safely administered, the company is now focusing on ensuring safe manufacturing and finalizing its FDA application. Upon FDA acceptance, the company would be able to commence Phase 1 clinical trials, marking the start of the journey toward US approval and addressing unmet medical needs. CERo plans to update shareholders on their progress, including presentations at investor conferences, potential growth of their intellectual property portfolio, and advancements in other programs beyond AML. Click here for more information CERo Therapeutics Holdings, Inc., (NASDAQ:CERO). Footnotes: [1] https://globalnews.ca/news/10428035/manitobas-first-car-t-cell-therapy-patient-declared-cancer-free/ [2] https://jamanetwork.com/journals/jama/article-abstract/2815500 [3] https://www.pennmedicine.org/cancer/navigating-cancer-care/treatment-types/immunotherapy/what-is-car-t-therapy Disclosure: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, CERo Therapeutics Holdings, Inc. Market Jar Media Inc. was paid $1,500 USD for the production and publishing of this article by CERo Therapeutics Holdings, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by CERo Therapeutics Holdings, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-cero. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of CERo Therapeutics Holdings, Inc. or such entities and are not necessarily indicative of future performance of CERo Therapeutics Holdings, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

June 06, 2024 08:30 AM Eastern Daylight Time

Image

Culturelle® Probiotics and Re:wild Team Up to ‘Protect the Gut Microbiome’

YourUpdateTV

A new campaign from Culturelle® Probiotics and global conservation non-profit, Re:wild, is highlighting the similarities between endangered ecosystems on Earth and the endangered ecosystem within: the human gut microbiome. Recently, Dr. Robin Moore from Re:wild, participated in a nationwide satellite media tour to discuss the new initiative. A video accompanying this announcement is available at: https://youtu.be/JT_Nv2wpwrU Earth’s ecosystems are what sustain us. They are our first line of defense against emerging diseases and climate chaos, and they provide everything from clean air and water to food and medicines. But research shows that the populations of mammals, birds, reptiles, amphibians and fish have declined by nearly 70% since 1970. And a loss of biodiversity can significantly disrupt an ecosystem – lowering its productivity and quality. The gut microbiome – made up of trillions of living, breathing bacterial species – is also facing a loss of biodiversity and is under constant siege from a variety of modern-day stressors, like anxiety, lack of sleep, and poor eating habits, that can put it out of balance and hinder its ability to thrive. This led the Culturelle brand to make a poignant connection between the vulnerable state of our gut microbiome and the other ecosystems of the world. The gut is a critical ecosystem — and it's at risk. Culturelle Probiotics and Re:wild have teamed up to draw attention to the similarities between the endangered ecosystems of our world and the ecosystem within – the human gut microbiome – and raise awareness on the importance of protecting biodiversity in all ecosystems, both inside and out. To learn more about the campaign, visit ProtectTheGut.com. About Dr. Robin Moore Dr. Robin Moore blends his scientific training with his passion for photography and storytelling to connect a broad audience with the urgency and opportunity for saving endangered species and critical ecosystems. Recognizing the importance of communications for challenging perceptions and changing behaviors, Robin has spearheaded innovative campaigns to raise the profile of too-often overlooked species. The Search for Lost Frogs, a global quest to find species missing for decades, attracted significant media attention and inspired the book, In Search of Lost Frogs, which was named one of The Guardian’s best nature books of 2014. Robin is an award-winning photographer and Senior Fellow of the International League of Conservation Photographers. The Search for Lost Species, a signature initiative of Re:wild, builds on this success. About Culturelle® Probiotics For more than 25 years, Culturelle® Probiotics have helped individuals, children and families support their health. Covering digestive, immune, feminine, and pediatric health, Culturelle® product formulations are based on science, utilizing clinically studied probiotics to support the unique benefits of each product. Plus, the ingredients are proven effective and work in harmony with the human body.* About Re:wild Re:wild protects and restores the wild. They have a singular and powerful focus: the wild as the most effective solution to the interconnected climate, biodiversity and human wellbeing crises. Re:wild brings together Indigenous peoples, local communities, influential leaders, nongovernmental organizations, governments, companies and the public to protect and rewild at the scale and speed we need. Learn more at rewild.org. © 2024 dsm-firmenich group, Culturelle® is a trademark of the dsm-firmenich group. * The Food and Drug Administration has not evaluated these statements. This product is not intended to diagnose, treat, cure, or prevent any disease. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 05, 2024 03:46 PM Eastern Daylight Time

Video

OncoCyte's Innovative Approach: Potential in Precision Diagnostics

RazorPitch OCX

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects. Amidst these challenges, OncoCyte Corporation (NASDAQ: OCX ) has emerged as an innovative player in the precision diagnostics market. The company's tests enhance clinical outcomes for patients undergoing organ transplants and cancer treatments. With recent strategic partnerships and regulatory advancements, OncoCyte has spearheaded transformative advancements in the field. OCX’s product portfolio includes VitaGraft, a clinical blood-based test for monitoring solid organ transplants, and GraftAssure, a research-use-only test for the same purpose. Additionally, DetermaIO and DetermaCNI are designed for oncology applications, predicting responses to immunotherapies and monitoring therapeutic efficacy, respectively. Partnerships In April 2024, OCX partnered with Bio-Rad Laboratories (NYSE: BIO) to commercialize the GraftAssure assay. This agreement leverages Bio-Rad's extensive reach and expertise in the life sciences sector, facilitating the co-marketing of GraftAssure in the U.S. and Germany. Bio-Rad holds exclusive global distribution rights outside these regions. This collaboration is pivotal for scaling OncoCyte's operations and meeting the growing demand for transplant diagnostics. The partnership also includes an option for Bio-Rad to acquire IVD commercial rights upon FDA clearance, subject to specific milestones. This option comes with a second equity investment into OncoCyte, reflecting Bio-Rad's confidence in the product's market potential. Riggs noted, "The QX600 ddPCR platform, along with their expertise in the life science market, makes Bio-Rad a natural partner for our transplant technology." Financial Performance OncoCyte's Q1 2024 financial results indicate a strategic focus on commercialization and cost-efficiency. The company reported gross proceeds of $15.8 million from an equity private placement, including a significant investment from Bio-Rad. This funding is crucial for advancing OncoCyte's product pipeline and expanding its market presence. Operational efficiency is evident, with OncoCyte reducing its cash burn to $3.9 million, reflecting a capital-efficient business model. The collaboration with Bio-Rad and the anticipated commercial launch of GraftAssure RUO test kits in Asia, the U.S., and the EU are expected to drive revenue growth and broaden the company's market reach. Riggs remarked, "The collaboration with Bio-Rad is pivotal for the upcoming launch of our GraftAssure RUO transplant rejection diagnostic test kit and central to our mission of developing accessible point-of-care diagnostics and continuous innovation in transplant rejection monitoring." Publication in New England Journal of Medicine OCX announced a significant milestone on May 30, 2024, with the publication of promising data on VitaGraft Kidney in the New England Journal of Medicine. This phase 2 study highlights VitaGraft Kidney’s potential to revolutionize kidney transplant care by accurately monitoring graft health through measuring donor-derived cell-free DNA (dd-cfDNA). For investors, this development signals substantial market potential. VitaGraft Kidney's ability to monitor therapeutic efficacy and detect disease recurrence opens new revenue streams. This test could become a standard in post-transplant care, driving repeated testing and long-term revenue. VitaGraft Kidney addresses a critical unmet need. Up to 20.2% of kidney transplant patients develop antibody-mediated rejection (AMR) within 10 years, with no FDA-approved drugs currently available for AMR management. The combination of VitaGraft testing and felzartamab therapy offers a promising solution, potentially improving patient outcomes and healthcare efficiency. OCX CEO Josh Riggs emphasized the breakthrough nature of this study, stating, “This positions VitaGraft Kidney as a crucial tool in managing transplant health. Our recent partnership with Bio-Rad expands our capacity to deliver these innovative solutions globally.” Riggs highlighted the test’s competitive edge in detecting AMR up to 10 months earlier than current protocols, enhancing patient care, and strengthening OncoCyte’s market position. The findings will be presented at the 2024 American Transplant Congress on June 3, 2024. This presentation is expected to further validate VitaGraft Kidney’s clinical value and could act as a catalyst for broader market adoption. OncoCyte’s latest publication not only validates VitaGraft Kidney’s clinical potential but also strengthens the company’s market position. As OCX continues to innovate and expand its market reach, investors can anticipate significant growth opportunities in the precision diagnostics sector. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by PCG Advisory Inc. to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

June 05, 2024 07:00 AM Eastern Daylight Time

DPH BIOLOGICALS DELIVERS NEXT GENERATION BIOLOGICALS WITH EXPANDED PORTFOLIO BUILT ON NOVEL TECHNOLOGY PLATFORM

DPH Biologicals

DPH Biologicals, a leading developer and supplier of agricultural biologicals, announced its new Prime platform that uses a patented production process for Bacillus spp., a leading plant growth rhizobacterium, to accelerate the germination of bacteria spores, supporting overall plant development while providing crops with more consistent resilience against heat, drought, and alkaline and saline soil conditions. “Historically biologicals have been dinged for inconsistent performance when used in a variety of environmental conditions. By utilizing a unique manufacturing process, we’ve enabled Bacillus spores to germinate faster resulting in more consistent performance especially in stressful conditions. Ultimately, Prime gives channel partners and growers more confidence in biologicals and allows them to differentiate from the plethora of microbial-based products on the market,” said Mick Messman, DPH Bio President and CEO. Kept in a dry, dormant state to germinate quicker, Prime spores colonize the root zone faster, capturing nitrogen while solubilizing potassium and phosphorus for more effective nutrient uptake. In a lab trial, Prime enabled more than 70% of Bacillus spores to germinate at temperatures as high as 98.6 degrees Fahrenheit, while those without Prime germinated less than 10% after 50 minutes. Additionally, nearly all spores with Prime germinated in high salt environments, while those that were not treated with Prime did not germinate. With exclusive rights, DPH Bio is the first to offer Prime-based products and has recently integrated Prime into several existing biofertilizers in its TerraTrove™ product line, including Envelix Prime available this fall and Essential™ Prime PAK available for the 2025 crop season. “We are excited to see results coming through our science-based approach to support our channel partners and growers. Powered by Prime, the next generation of biologicals delivers higher quality sustainable options that consistently work," said Messman. For more information about DPH Bio’s technology platforms – RegenAphex™ and Prime, as well as DPH Bio’s expanded product portfolio, visit www.dphbio.com. About DPH Biologicals DPH Biologicals, LLC attracts, develops and scales technologies improving broad market access and simplifying the grower experience with biologicals. Based on investments in scientific research, field testing, partner relationships and product development, and leadership-owned since 2024, DPH Bio yields success through science and relationships, standing at the leading edge of clarity, trust and proven, profitable solutions for agricultural biologicals. For more information, visit www.dphbio.com Contact Details AgTech PR for DPH Bio Georgie Smith georgie@agtechpr.com Company Website http://www.dphbio.com

June 04, 2024 08:30 AM Eastern Daylight Time

Image

Novus Reports Q1 Results And Key Success Factors Following DEA Rescheduling

Novus Acquisition & Development Corp

Miami, Florida - ( ThriveNewsWire ) - Novus Acquisition & Development Corp d/b/a Novus Cannabis MedPlan (OTC Markets: ( NDEV ) is a leading national supplemental health insurance carrier and pioneer in offering cannabis in health plans for recreational and medicinal users. It released its update on its Q1 2024 results, Rx Dispensing Platform, and Key Elements that fuel its success after the Drug Enforcement Agency (DEA) announced that cannabis will be rescheduled. Novus Cannabis MedPlan (Novus) has been integrating cannabis into health plans since 2015. With a network of over 1,200 agents, brokers, and dispensaries, Novus aims to make cannabis-based treatments more affordable and accessible through insurance plans, benefitting a wider range of consumers. Here are three key highlights that contribute to Novus' success. 1) Financial Snapshot: The company utilizes a receivable-based business model with minimal overhead and no convertible debt, demonstrating consistent organic growth year over year. No Dilution: No common stock has been issued after June 15, 2021. No Sales of Insider Shares: For close to 3 years Gross Revenue Increase: During this reporting period, Gross Revenue increased by 6.8% compared to March 31, 2024 and 2023, respectively, Net Revenue Increase: During this reporting period, EBITDA increased by 19.47% compared to March 31, 2024, and 2023. Profit Margin: During the reporting period, the company experienced a gradual increase in gross profit margins, with margins of 43.14% in 2023 and 45.2% in 2024 Cash and Cash Equivalents: There was an increase of 1.8% compared to the financial reporting periods on March 31, 2024, and December 31, 2023. This is in contrast to the higher increase of 6.84% in the period from March 31, 2023, to 2024. Debt Transparency: Frank Labrozzi, the CEO, is owed $158,061. He has no plans to exercise the call provision, and this debt instrument has no equity conversion provision. Leak Out Vendor Shares: All vendors who received treasury-issued stock must gradually sell their shares. The selling amount is determined based on 15% of the average daily trading volume over the past 30 days. 2) Introducing the Rx Dispensing Platform Novus is strategically positioning its cannabis health plans to become a prominent player in mainstream healthcare insurance by acquiring an Rx Dispensing Platform tech stack. Frank Labrozzi, CEO of Novus, stated, "This advancement will significantly impact cannabis in health plans. By promoting collaboration between brands and dispensaries, we aim to empower policyholders with more choices, enabling them to purchase the brands they prefer at any dispensary. Cannabis brands can use the platform to connect directly with dispensaries and showcase their products at no cost. This will improve product distribution efficiency, increase brand visibility, provide real-time inventory data, and facilitate product research for the policyholder. An added bonus to For Rec Users: This platform serves recreational users who prefer not to disclose personal information like their policyholder status to access plan benefits. Instead, users can discreetly order services for a small subscription or transaction fee. 3) Key Success Factors Midwest Expansion: Novus has partnered with Heya Wellness, a prominent cannabis company in Missouri, to offer MedPlans to 4.3 million potential policyholders in the Midwest. By leveraging Missouri's favorable reciprocity laws, Novus aims to maximize the benefits for our sales hub based in St. Louis. Health Carrier Alliances Integration with Traditional Healthcare: By treating cannabis as a traditional pharmaceutical product and including it in insurance plans, Novus could help normalize cannabis use for medical, recreational, and non-users. Now that there is federal approval, Novus bridges traditional healthcare and the cannabis industry, enhancing major healthcare carriers who have expressed interest in integrating Novus' cannabis-based prescription plans into their benefits packages, establishing a connection between the two industries. Compassionate Care Act (CCA): The CCAs, which the Supreme Court sanctions, typically focus on making medical marijuana accessible to workplace patients with specific conditions. Human Resources departments are revising workplace policies to allow employees to access medical marijuana through employer-sponsored health plans. Novus plans to cover some costs through tax-deductible health savings and health reimbursement accounts. Opioid Settlement Framework: The opioid settlement framework is a legal agreement aimed at resolving litigation against pharmaceutical companies and health carriers accused of contributing to the opioid crisis. It includes $50 billion for prevention, treatment, and recovery programs with the goal of mitigating the crisis' impact and preventing future misuse. Novus is playing a crucial role in reducing opioid use by offering states and private organizations alternative treatment options through our developed health plans that help patients transition from opioids to medical cannabis. Compliance with the Veteran’s Affairs (VA): Veterans are increasingly interested in utilizing cannabis for treatment—over 88% support medical cannabis programs. Novus has developed health plans following VA guidelines to integrate cannabis benefits for veterans. In closing: As Novus adjusts to the positive changes in federal cannabis regulation, we are prepared to utilize our niche approach to cannabis in health plans, which utilizes a receivables-based business model. This approach strategically enables us to organically invest in critical areas such as marketing, improving engagement with policyholders and providers, and establishing a reliable cash flow management system. This positions Novus as a significant player in the fast-evolving cannabis integrated into health insurance plans. Do your research on our company to understand our potential in shaping the future of healthcare. Visit our Investor Relations page to see for yourself. About Novus Further Research: Financial Filings: Click Here Quote: Click Here Website Click Here Investor's Page Click Here Video Of Investment Highlights: Click Here Novus Acquisition & Development Corp. (NDEV) operates through its subsidiary, WCIG Insurance Services, Inc., offering health insurance and related insurance solutions in states with legal medical marijuana programs. With a robust infrastructure covering various insurance lines, including health, life, and fixed annuities, Novus is a leading health insurance carrier, using two key indicators to gauge value and performance. The Benefit Monetization Ratio measures the annual total of monetized policies, offset by the operating cost ratio, a Balance Sheet line item derived from Net Asset Value and calculated to the Price Book Value. Novus' medical cannabis benefits package operates as an outside developer. It does not engage in any activities related to the cultivation, handling, transportation, growth, extraction, dispensing, sale, marketing, vending, delivery, supply, circulation, or trade of cannabis or any substances violating United States law or the Controlled Substances Act. The company adheres strictly to state and federal laws and has no intentions to violate them in the future. It is important to note that statements regarding specific products have not been evaluated by the United States Food and Drug Administration (FDA) and should not be interpreted as intended to diagnose, treat, cure, or prevent disease. The information provided in press releases and product labels is for informational purposes only and should not be considered a substitute for advice from qualified healthcare professionals. Novus respects the individual transactions involving cannabis, which are solely between state-licensed dispensaries and registered patients. However, it's worth noting that state laws may conflict with the federal Controlled Substances Act. The current administration has indicated that federal law enforcement agencies will not prioritize prosecuting those complying with state-designated laws concerning medical marijuana usage and distribution. Nevertheless, changes in government policies and consolidation could impact the provider network, and there is no assurance that future administrations will not alter this stance. While Novus does not engage in the harvest, distribution, or sale of cannabis or cannabis-related products, the company could be affected if there were any shifts in enforcement by federal or state governments concerning existing laws. Such changes could result in significant financial implications for Novus and other industry players. Forward-Looking Statements This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. Investor Contact Information Investor Website 855-228-7355 Email: pr@getnovusnow.com Contact Details Novus Acquisition Frank Labrozzi +1 305-467-6699 frank@ndev.biz Company Website https://getnovusnow.com/

June 04, 2024 08:00 AM Eastern Daylight Time

AGC Biologics Completes Copenhagen Campus Expansion, Doubling Single-use Mammalian Bioreactor Capacity at Site

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced at BIO International the completion of its new manufacturing building at the AGC Biologics Copenhagen campus. The completed work doubles the site’s single-use bioreactor capacity for mammalian services and allows it to produce 150 more batches of drug product each year. The expansion adds 19,000 m2 of space in an ultramodern building that houses a large manufacturing floor, expanded quality control and process development lab space, utilities to support all operations and prevent outages caused by natural disasters, and a fully dedicated warehouse to serve the entire AGC Biologics Copenhagen campus. The new AGC Biologics Copenhagen manufacturing building is already in production with its first customer, a phase II/III clinical product. AGC Biologics announced the planned expansion in November 2020, investing roughly $200 million into the work. One-of-a-kind single-use manufacturing offering The new manufacturing area offers 8 x 2,000 L single-use bioreactors with two seed trains, as well as two independent downstream suites – [CW1] more than doubling the existing capacity offered at this site for mammalian-based projects. AGC Biologics Copenhagen is now one of the only sites in the world with multiple single-use bioreactor systems of this magnitude capable of producing batches at high-levels of clinical and commercial production. Further, for developers needing to transfer in an existing process, AGC Biologics Copenhagen’s multiple single-use suites give the site greater flexibility to take on technical transfers and perform like-for-like process and knowledge activities for products entering the facility, eliminating lag time associated with onboarding a new CDMO. AGC Biologics has been a leader in single-use technology over the last decade, and it is one of the largest CDMO networks in the industry offering flexible and scalable single-use bioreactors systems. The news comes after AGC Biologics announced an end-to-end protein biologics drug product partnership with Dutch-based BioConnection in late May. The alliance provides a secure and full-service “gene-to-vial” offering for biopharma developers with drug substance development, manufacturing and aseptic fill and finish capabilities for drug products. “AGC Biologics Copenhagen site continues to be one of the most active in our network with all the necessary commercial approvals – FDA, EMA, HCA, PMDA, ANVISA etc. – and we are more than happy to offer the capacity and capabilities our current and future customers will look for with this completed expansion,” said Christoph Winterhalter, CBO, AGC Biologics. “The expansion, combined with our new drug product alliance, demonstrates AGC Biologics’ agility to meet all the needs developers may have, from pre-clinical through commercial.” AGC Biologics’ Copenhagen site core teams of scientists have more than 25 years of expertise in biopharmaceutical development and manufacturing, including seven commercial products brought to market. The site offers pre-clinical through commercial production for protein biologics services using mammalian and microbial systems. It has a gold EcoVadis Sustainability Rating for its environmental, health and sustainability practices. “I am extremely proud of the work and collaboration of everyone at our site over the last several years, it is truly remarkable to see what we can accomplish by working together. We are eager to offer more of the important capabilities the industry is looking for to support patients in need,” said Andrea C. Porchia, General Manager, AGC Biologics Copenhagen. To learn more about AGC Biologics Copenhagen, visit www.agcbio.com/facilities/copenhagen. For more information about AGC Biologics’ global CDMO services go to www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

June 04, 2024 12:00 AM Pacific Daylight Time

Mphasis and Classiq Partner to Drive Quantum Innovation

Classiq Technologies

Mphasis, (BSE: 526299; NSE: MPHASIS), an Information Technology (IT) solutions provider specializing in cloud and cognitive services, today announced its strategic partnership with Classiq, a leading quantum software company to demonstrate and commercialize industry solutions powered by Quantum. The strategic partnership aims to accelerate the adoption of quantum solutions for enterprises by integrating them into its operations. The collaboration is committed to fostering innovation and redefining technological boundaries and paving the way for a quantum-powered future. Classiq leads in quantum computing software and has developed a platform for faster and more efficient quantum algorithm design. Mphasis will focus on building industry solutions in sectors such as BFSI, Lifesciences, Healthcare, Supply Chain & Logistics, Chemistry, utilizing these advanced algorithms. By leveraging Classiq’s quantum platform, Mphasis will develop industry-specific intellectual properties (IPs) and will also jointly market and implement customer IPs, execute customer projects, and provide support for the commercialization of Classiq’s platform and IPs. Additionally, Mphasis’ Quantum Initiative, launched in 2020 within the Applied R&D division, NEXT Labs, aims to facilitate our client's transition to the quantum era. The adoption model comprises awareness-building, assessment, and consulting workshops, as well as the development and implementation of quantum solutions in key domains such as optimization, artificial intelligence, simulation, and cybersecurity. Within the realm of quantum computing, the company’s priorities include applied research, the creation of industry-specific solutions and intellectual properties, thought leadership dissemination, building robust partnerships, and leveraging a design thinking approach to drive adoption. “We are thrilled to announce our collaboration with Classiq and leveraging their expertise to unlock the vast potential of quantum computing. This partnership enables us to combine our industry knowledge with cutting-edge quantum technology, to innovative solutions tailored to our clients' needs. Together we hope to lead the way in initiating and implementing state-of-the-art quantum solutions that redefine the boundaries of our field," said Srikumar Ramanathan, Chief Solutions Officer, Mphasis. "Classiq is proud to be partnering with Mphasis to support scalable enterprise quantum computing software development. Together we combine depth of industry domain knowledge and quantum expertise with the technology needed to implement sophisticated optimized quantum computing programs for our clients," said Nir Minerbi, CEO and Co-Founder, Classiq Technologies. By synergizing Mphasis' domain expertise with Classiq's quantum computing acumen, the collaboration is poised to unlock newer possibilities and redefine industry benchmarks. Quantum computing's ability to tackle previously unsolvable problems opens doors for entirely new discoveries and innovations. National Institute of Standards and Technology’s report states that quantum computing could lead to breakthroughs in areas like materials science, drug discovery, and financial modelling. McKinsey & Company estimates a $106B potential quantum technology market size by 2040. The alliance between Mphasis and Classiq represents a fusion of expertise and innovation, with Classiq's cutting-edge quantum development platform complemented by Mphasis' extensive industry knowledge. Together, the companies aim to pioneer groundbreaking quantum solutions that will reshape sectors primed for transformative change. Classiq’s platform enables both beginner and expert designers to rapidly generate, analyze, and execute quantum circuits. The collaboration reflects the shared dedication of Mphasis and Classiq, showcasing a commitment to pioneering quantum computing applications across diverse industry sectors. Apart from this, in June 2021, Mphasis along with the Government of Alberta, and the University of Calgary signed an MoU to announce the launch of the world-leading Quantum City - Canada. The strategic partnerships were to accelerate talent development and the development of a quantum computing ecosystem in Calgary, driving R&D in the technology sector. In June 2022, Mphasis deepened its commitment to Canada by announcing a delivery center in Calgary, opening the center in Alberta for business. The Mphasis business ecosystem was positioned to reinforce the region's reputation as a leading hub for digital transformation, AI, quantum computing, and more, and contribute to Canada's growing digital sector. About Mphasis Mphasis’ purpose is to be the “Driver in Driverless Car” for Global Enterprises by applying next-generation design, architecture, and engineering services, to deliver scalable and sustainable software and technology solutions. Customer centricity is foundational to Mphasis, and is reflected in the Mphasis’ Front2Back ™ Transformation approach. Front2Back™ uses the exponential power of cloud and cognitive to provide hyper-personalized (C= X2C2TM =1) digital experience to clients and their end customers. Mphasis’ Service Transformation approach helps ‘shrink the core’ through the application of digital technologies across legacy environments within an enterprise, enabling businesses to stay ahead in a changing world. Mphasis’ core reference architectures and tools, speed and innovation with domain expertise and specialization, combined with an integrated sustainability and purpose-led approach across its operations and solutions are key to building strong relationships with marquee clients. Click here to know more. ( BSE: 526299; NSE: MPHASIS ) About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform (IDE, compiler and OS) with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equips customers to take full advantage of the quantum computing revolution. A low-code development environment that automates quantum programming ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Classiq also works closely with advanced computation hardware providers providing software for use with quantum computers, HPC and quantum simulators. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, join the Slack community, or try the Classiq platform. Contact Details Rainier Communications Michelle Allard McMahon +1 781-718-3248 classiqPR@rainierco.com Mphasis Corporate Communications Deepa Nagaraj +1 646-424-5160 deepa.nagaraj@mphasis.com Mphasis Corporate Communications Sumana Bhat +91 99029 80980 sumana.bhat@mphasis.com Company Website http://www.classiq.io/

June 04, 2024 02:04 AM Eastern Daylight Time

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Candel Therapeutics

By Jeremy Golden, Benzinga Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023. The randomized, controlled clinical trial is specifically looking into the safety and efficacy of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection – if possible – in borderline resectable pancreatic ductal adenocarcinoma (PDAC). Very encouraging results were recently reported by the Needham, Massachusetts-based company. Patients reached an estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group in PDAC. At 24 months, the survival rate was 71.4% in CAN-2409 treated patients compared to only 16.7% in the control group after chemoradiation. Thus, prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC. Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients in the randomized control SoC chemotherapy group remained alive at the data cut-off (50.6 months). No new safety signals were observed, providing further support that multiple injections of CAN-2409 are generally well tolerated. Additionally, there were no dose-limiting toxicities or cases of pancreatitis reported. Previous analysis of resected tumors showed dense aggregates of immune cells – including CD8+, cytotoxic tumor-infiltrating lymphocytes and dendritic cells – in PDAC tissue after CAN-2409 administration. This reinforces the potential of CAN-2409 to activate a robust antitumoral immune response in patients with cancer also in ‘cold’, immunosuppressive tumors like PDAC. “Given the frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed,” said Garrett Nichols, MD, MS, Chief Medical Officer of Candel. “We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data in this randomized clinical trial. CAN-2409 was generally well tolerated without significant additional local or systemic toxicity when added to SoC chemoradiation.” Candel’s most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf, replication-defective adenovirus designed to induce an individualized, systemic immune response against the tumor. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. More than 1,000 patients have been dosed with CAN-2409 to date, with a favorable reported tolerability profile and proof of concept in each indication that the company is currently pursuing. CAN-2409 is injected directly into the tumor or target tissue using a localized injection method that is akin to the standard approach for in situ vaccination to elicit an immune response against the injected tumor and uninjected metastases. Long-term survival data in PDAC was recently updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to Candel Therapeutics for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023. More recently, the FDA also granted Orphan Drug Designation. “The failure of conventional immunotherapy to improve outcomes in pancreatic cancer is attributed to the highly immunosuppressive tumor microenvironment, which is largely devoid of immune cells,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “The immunological changes induced by CAN-2409, evident in the pancreatic tissue and the peripheral blood after administration, suggest that CAN-2409 is able to change the balance between the tumor and the patient’s anti-tumor immune response, which can convert progressive cancer into a chronic disease associated with improved survival.” Featured photo by National Cancer Institute on Unsplash. Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. This article includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Aljanae Reynolds +1 617-916-5445 areynolds@wheelhouselsa.com Company Website https://www.candeltx.com/

June 03, 2024 08:30 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 206